Objective To observe the clinical efficacy of dendritic cell-cytokine-induced killer cell (DC-CIK) combined with interleukin (IL)-2 in treatment of renal cell carcinoma.Methods A total of 60 patients with renal cell carcinoma after radical nephrectomy were randomly divided into treatment group and control group.Thirty cases in treatment group were given DC-CIK cells combined with IL-2 treatment.Thirty cases in control group were treated with IL-2 treatment.The immune function,quality of life,survival rate and adverse reactions were analyzed in two groups.Results Compared with before treatment,the percentages of CD3+,CD4+,CD4+/CD8+ ratio and CD16+CD56+ increased and CD8+ decreased significantly in treatment group(P ＜ 0.05).In control group,there was no significant change before and after treatment in the percentages of CD3+,CD4+,CD4+/CD8+ ratio,CD16+ CD56+ and CD8+(P ＞ 0.05).Quality of life of 83.3％(25/30)patients in treatment group was improved,56.7％(17/30) patients in control group was improved,there was significant difference between two groups (P ＜ 0.05).The 1-year survival rate in treatment group and control group were 93.3％ (28/30),83.3％ (25/30),and the 1-year recurrence rate in two groups were 6.7％ (2/30)and 13.3％ (4/30),there were no significant difference between two groups (P ＞ 0.05).There were no significant statistically in the incidence of adverse reactions between two groups (P ＞ 0.05).Conclusion DC-CIK cells combined with IL-2 in treatment of renal cell carcinoma after radical nepbrectomy can improve patients' immune function and quality of life.